ClinicalTrials.gg
Status unknownNCT05970432Updated Aug 1, 2023

A Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

A Phase 2 interventional study of TQH2722 injection 300mg-150mg and TQH2722 injection 600mg-300mg in Atopic Dermatitis, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Status unknown at 32 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-08-01.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2023), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 206 studies in Dermatitis, Atopic with a site in China — 64 open to participants now, 82 under way, 29 of them phase 3. Dermatitis, Atopic · China.

Planned enrollment
98th of 190
160 · median 164
Started
2023
with 38 others
Phase 2
58 of 206
16 open now
Registered
79th of 206
by date

Among the 206 studies in Dermatitis, Atopic with a site in China, this one is the 98th largest by planned enrollment of the 190 interventional ones that give a count, is one of 39 that started in 2023, is one of 58 in phase 2, and was the 79th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

64 of the 206 studies in Dermatitis, Atopic with a site in China are open now. Recruiting first, the newest first:

59 more — sign in →

All 64 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Dermatitis, Atopic with a site in China, or all of them as a file.
02

Study summary

This phase II clinical trials is multicenter, randomized, double-blind, placebo-controlled to assess the effectiveness and safety of TQH2722 injection in the treatment of subjects with moderate to severe atopic dermatitis.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-65 (when signing ), regardless of gender;
  • Meets 2014 American Academy of Dermatology (AAD) criteria with diagnosis of atopic dermatitis (AD); In addition, history of AD prior to screening ≥ 6 months; Eczema was previously diagnosed but met the 2014 AAD criteria and can still be enrolled.
  • Patients with moderate to severe AD at screening and baseline visit (shall meet all 3 criteria as follows):

    1. total area of AD lesions≥ 10% BSA;
    2. IGA ≥3 points;
    3. EASI ≥ 16 points;
  • Baseline peak pruritus NRS ≥4 (The average peak pruritus intensity score in baseline peak pruritus NRS will be calculated based on the average of the peak pruritus intensity NRS score (daily score range 0-10) for each day during the 7 days prior to randomization. A minimum of 4 days out of 7 days of scoring is required to calculate the baseline average score. If the patient's reporting days are less than 4 days in the 7 days prior to the planned randomization date, randomization should be postponed until the requirements are met, but not beyond the maximum period of 14 days for screening);
  • 6 months prior to the screening period, insufficient response to stable (≥1 month) topical (TCS) or calcineurin inhibitors (TCI) (insufficient response defined as at least 28 days even if the daily regimen of moderate-high potency TCS (± topical TCI, if applicable) is at least 28 days, or to the maximum recommended course of treatment (eg, ultra-potent TCS - 14 days) in the product prescribing information (whichever is shorter), Failure to achieve or maintain disease remission or low disease activity (equivalent to IGA 0 [=none]-2 [=mild]). or patients who have received a record of systemic treatment (adequate dose, adequate course) of AD in the past 6 months are also considered to have insufficient response to topical drug therapy, and may be selected for trial after appropriate drug elution and approval by the sponsor);
  • Before the first dose, subjects must have continuously used the emollient twice a day for at least 1 week and maintained throughout the trial (Note: the emollient is provided by the sponsor);
  • Be able to read and understand, and be willing to sign informed consent forms;
  • Willingness and compliance with research visits and related procedures;
  • Female participants of childbearing age should agree that (e.g., intrauterine devices, pills, or condoms) must be used during the study period and for 6 months after the end of the study; Negative serum pregnancy test within 7 days prior to first dose and must be a non-lactating subject; Male subjects should agree that contraception must be used during the study period and for 6 months after the end of the study period.

Exclusion criteria

Exclusion Criteria:

  • Participants who received the following treatments within the following limited time prior to randomization:

    1. Have used any of the following treatments within 4 weeks or the investigator believes that the following treatments may be required: /immunomodulatory drugs (eg, systemic glucocorticosteroids, cyclosporine, mycophenolate mofetil, interferon γ (IFN-γ), azathioprine, and methotrexate); AD phototherapy;
    2. Oral Janus Kinase (JAK) inhibitors (including but not limited to upadacitinib) used within 2 weeks;
    3. Received systemic traditional Chinese medicine (TCM) treatment within 4 weeks; or within 1 week, topical TCM;
    4. Treated with leukotriene inhibitors within 4 weeks;
    5. Treated with topical preparations of TCS or TCI or phosphodiesterase 4 (PDE⁃4) inhibitors within 2 weeks;
    6. Treatment with the following biologics: any cell depleting agent, including but not limited to rituximab: within 6 months or until the lymphocyte count returns to normal, whichever is longer; Other biologics: 5 half-lives (if half-life known) or 12 weeks (whichever is longer); Within 4 weeks, receive regular phototherapy (including but not limited to narrow-spectrum UVB, psoralen longwave ultraviolet therapy, etc.) or use artificial sunbathing sheds/rooms;
    7. Within 12 weeks, receive live (attenuated) vaccine;
    8. Chronic active or acute infection requiring systemic treatment with antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks, or superficial skin infection within 1 week prior to baseline visit. After the infection resolves, screening can be renewed;
    9. Antihistamines (including oral, nasal, and topical preparations) within 1 week;
  • Abnormal physical examination results during screening or any of the following laboratory tests:

    1. \< 110 g/L
    2. White blood cell (WBC) \< 3.5 x 10\^9/L
    3. count \< 125 x 10\^9/L
    4. Neutrophils\< 1.75 x 10\^9/L • (AST)/alanine aminotransferase (ALT) >1.5 x (ULN)
    5. Total > 1.5 x ULN (except indirect bilirubin elevation secondary to Gilbert syndrome)
    6. Creatinine > 1.5 x ULN
    7. Creatine phosphokinase (CPK) > 2 x ULN
  • There are cutaneous comorbidities that may interfere with the study assessment, including but not limited to scabies, seborrheic dermatitis, cutaneous T-cell lymphoma, psoriasis, etc
  • Concomitant other serious medical conditions that, at the discretion of the investigator, may adversely affect participants' participation in this study, including, but not limited to: short , history of uncontrolled diabetes ( ≥ 9%), cardiovascular disease (eg, grade III or IV heart failure, graded according to the ), severe kidney disease (eg, patients on dialysis), hepatobiliary disease (e.g., class B or C), neurological disease (e.g., demyelinating disease), Patients with important active diseases (eg, lupus, inflammatory bowel disease, rheumatoid arthritis, etc.), as well as other severe endocrine, gastrointestinal, metabolic, pulmonary, or lymphatic diseases.
  • Have a history of known or suspected immunosuppression, including invasive opportunistic infections (e.g., histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, and aspergillosis), even if the infection has resolved; or unusual frequent, recurrent, or long-term infections (at the investigator's discretion);
  • Subjects with any type of active or a history of malignancy (except cervical cancer or non- cutaneous squamous cell carcinoma, basal cell carcinoma and papillary thyroid carcinoma) that has been cured for more than 5 years prior to the screening period;
  • Computed Tomography (CT) of the chest shows active or occult tuberculosis or a history of contact with an open tuberculosis (TB) subject within the past 6 months. If the laboratory T cell spot test for tuberculosis infection test (or other tuberculosis diagnostic test) is positive, its activity is judged in combination with the medical history, clinical manifestations, etc., and the investigator determines whether it can be enrolled;
  • Active hepatitis during the screening period, or positive for surface antigen (HBsAg), or positive for hepatitis B core antibody (HBcAb);
  • History of (HIV) infection, or positive HIV serological results at screening, and positive antibodies to treponema pallidum during screening
  • Positive for treponemal pallidum antibodies during screening
  • Parasitic infection related to any of the following is excluded:

    1. Routine inspection of worm eggs during the screening period;
    2. History of parasitic infection within 6 months prior to the screening period, except for cured trichomoniasis;
  • Have participated in clinical trials of other drugs or medical devices within 12 weeks prior to screening
  • During the period of participation in this study, participants had planned surgical procedures
  • Pregnant or lactating women
  • People who are alcoholic, drug addicts, and known drug dependents
  • In the judgment of the investigator or sponsoring medical auditor, it is believed that there are any medical or psychiatric symptoms that put the subject at risk, interfere with participation in the study, or interfere with the interpretation of the results of the study.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    TQH2722 injection 300mg-150mg

    Participants received subcutaneous injection of 300 mg TQH2722 injection + 600 mg placebo on day 1, followed by subcutaneous injection of 150 mg TQH2722 injection + 300 mg placebo on days 15, 29, 43, 57, 71, 85, 99.

    Drug: TQH2722 injection 300mg-150mg

  • Experimental
    TQH2722 injection 600mg-300mg

    Participants received subcutaneous injection of 600 mg TQH2722 injection + 300 mg placebo on day 1, followed by subcutaneous injection of 300 mg TQH2722 injection + 150 mg placebo on days 15, 29, 43, 57, 71, 85, 99.

    Drug: TQH2722 injection 600mg-300mg

  • Experimental
    TQH2722 injection 900mg-450mg

    Participants received subcutaneous injection of 900 mg TQH2722 injection on day 1, followed by subcutaneous injection of 450 mg TQH2722 injection on days 15, 29, 43, 57, 71, 85, 99.

    Drug: TQH2722 injection 900mg-450mg

  • Placebo comparator
    TQH2722 injection matching Placebo

    Subjects received 900mg placebo injection subcutaneously on day 1, followed by 450mg placebo injection on days 15, 29, 43, 57, 71, 85, 99.

    Drug: TQH2722 injection matching Placebo

Interventions

  • TQH2722 injection is a fully human monoclonal antibody that interfering with the signal cascade.

  • TQH2722 injection is a fully human monoclonal antibody that thereby interfering with the signal cascade.

  • TQH2722 injection is a fully human monoclonal antibody that thereby interfering with the signal cascade.

  • DrugTQH2722 injection matching Placebo

    Placebo without active substance.

06

What researchers measure

Primary outcomes

  1. Eczema area and severity (EASI)-75 (≥75% improvement from baseline).

    Proportion of participants with eczema area and severity (EASI)-75 (≥75% improvement from baseline) at week 16.

    Time frame: Up to 16 weeks.

Secondary outcomes

  1. Investigator's general assessment (IGA)

    Proportion of subjects with, the investigator's overall assessment (IGA) of 0 or 1 (6-point in total) at week 16.

    Time frame: Up to 16 weeks.

  2. Eczema area and severity (EASI)-90 (≥90% improvement from baseline).

    Proportion of participants with EASI-90 at week 16.

    Time frame: Up to 16 weeks.

  3. Eczema area and severity (EASI)

    Percentage change in EASI score from baseline to week 16;

    Time frame: Up to 16 weeks.

  4. Change in investigator's general assessment (IGA)

    Change (or percentage change) in IGA score from baseline to week 16;

    Time frame: Up to 16 weeks.

  5. Body surface area (%BSA)

    %BSA change from baseline to week 16

    Time frame: Up to 16 weeks.

  6. Treatment Emergent Adverse Events (TEAE)

    Incidence of TEAE from baseline to week 20 determined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTC AE) V5.0.

    Time frame: Up to 20 weeks.

  7. Incidence of anti-drug antibodies (ADAs)

    The incidence of anti-drug antibodies (ADAs) of subjects and their titer, the incidence of neutralizing antibodies (Nab). If the subject is tested positive for ADA, a neutralizing antibody is added in the test.

    Time frame: Up to 24 weeks.

  8. Incidence of neutralizing antibodies

    If the subject is tested positive for ADA, a neutralizing antibody is added.

    Time frame: Up to 24 weeks.

  9. Peak Itch numerical rating scale (NRS)

    Peak Itch NRS changes from baseline to week 16. The total score is 10, with higher scores indicating more severe pruritus.

    Time frame: Up to 16 weeks.

  10. Dermatology Life Quality Index (DLQI) scores

    DLQI scores change from baseline to week 16, the scores are rated as None, Not Relevant, and 0-3, with higher values representing more serious disease.

    Time frame: Up to 16 weeks.

07

Study locations

32 of 32 sites recruiting
  • The First Affiliated Hospital of Wannan Medical College
    Wuhu, Anhui 241000, China
    Recruiting
  • Dermatology Hospital, Southern Medical University
    Guangzhou, Guangdong 510030, China
    Recruiting
  • The Second Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong 510260, China
    Recruiting
  • Shenzhen People's Hospital
    Shenzhen, Guangdong 518020, China
    Recruiting
  • Affiliated Hospital of Guilin Medical University
    Guilin, Guangxi 541001, China
    Recruiting
  • Affiliated Hospital of Hebei Engineering University
    Handan, Hebei 056002, China
    Recruiting
  • The Forth Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050000, China
    Recruiting
  • The second affiliated hospital of harbin medical university
    Harbin, Heilongjiang 150000, China
    Recruiting
  • Puyang District Hospital of Anyang City
    Anyang, Henan 455000, China
    Recruiting
  • The First People's Hospital of Nanyang
    Nanyang, Henan 473000, China
    Recruiting
  • People's Hospital of Henan province
    Zhengzhou, Henan 450003, China
    Recruiting
  • Shiyan Renmin Hospital
    Shiyan, Hubei 442000, China
    Recruiting
  • Renmin Hospital of Wuhan University
    Wuhan, Hubei 430000, China
    Recruiting
  • The third xiangya hospital of central south university
    Changsha, Hunan 410013, China
    Recruiting
  • Qian-jin Lu
    Nanjing, Jiangsu 210042, China
    Recruiting
  • Affiliated Hospital of Jiujiang University
    Jiujiang, Jiangxi 332000, China
    Recruiting
  • The Second Hospital of Jilin University
    Changchun, Jilin 130041, China
    Recruiting
  • Panjin Liaoyou Gem Flower Hospital
    Panjin, Liaoning 124000, China
    Recruiting
  • The First Affiliated Hospital of China Medical University
    Shenyang, Liaoning 110000, China
    Recruiting
  • Air Force Medical University
    Xi'an, Shaanxi 710032, China
    Recruiting
  • The Second Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shaanxi 710061, China
    Recruiting
  • Shengli Oil Field Central Hospital
    Dongying, Shandong 25700, China
    Recruiting
  • Shandong First Medical University Affiliated Dermatology Hospital
    Jinan, Shandong 250022, China
    Recruiting
  • Qilu Hospital of Shandong University
    Jinan, Shandong 250063, China
    Recruiting
  • The Affiliated Hospital Of Qingdao University
    Qingdao, Shandong 266000, China
    Recruiting
  • Huashan Hospital Affiliated to Fudan University
    Shanghai, Shanghai 200040, China
    Recruiting
  • Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital
    Tianjin, Tianjin 300122, China
    Recruiting
  • Xinjiang Uygur Autonomous Region People's Hospital
    Ürümqi, Xinjiang Uygur Autonomous Region 830000, China
    Recruiting
  • The First Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan 650000, China
    Recruiting
  • The First Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310003, China
    Recruiting
  • The Second Affiliated Hospital Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310009, China
    Recruiting
  • The First People's Hospital of Wenling
    Wenling, Zhejiang 317500, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Mar 2024, 9 months after the start.

Of 195 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's planned 9 months is below that.

Counting every sponsor, half of 223 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2023
First posted
Aug 1, 2023
StartActual
Jun 19, 2023
Primary completionEst.
Mar 2024
CompletionEst.
Mar 2024
Last update
Aug 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05970432
Responsible party
Sponsor
First posted
Aug 1, 2023
Start date
Jun 19, 2023
Primary completion
Mar 2024 (estimated)
Completion
Mar 2024 (estimated)
Last update
Aug 1, 2023

Study contacts

Qian-jin Lu, Doctor
Contact
qianlu5860@gmail.com
+86 13787097676

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TQH2722

Start the discussion